Cargando…

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis

BACKGROUND & AIMS: The safety, tolerability, and efficacy of the non-bile acid farnesoid X receptor agonist tropifexor were evaluated in a phase II, double-blind, placebo-controlled study as potential second-line therapy for patients with primary biliary cholangitis (PBC) with an inadequate urso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schramm, Christoph, Wedemeyer, Heiner, Mason, Andrew, Hirschfield, Gideon M., Levy, Cynthia, Kowdley, Kris V., Milkiewicz, Piotr, Janczewska, Ewa, Malova, Elena Sergeevna, Sanni, Johanne, Koo, Phillip, Chen, Jin, Choudhury, Subhajit, Klickstein, Lloyd B., Badman, Michael K., Jones, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576902/ https://www.ncbi.nlm.nih.gov/pubmed/36267872 http://dx.doi.org/10.1016/j.jhepr.2022.100544

Ejemplares similares

The effect of Farnesoid X receptor agonist tropifexor on liver damage in rats with experimental obstructive jaundice
por: Kilavuz, Huseyin, et al.
Publicado: (2021)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
por: Badman, Michael K., et al.
Publicado: (2019)

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
por: Trauner, Michael, et al.
Publicado: (2019)

Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
por: Hernandez, Eloy D., et al.
Publicado: (2019)

Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis
por: Milkiewicz, Malgorzata, et al.
Publicado: (2016)

The Immunogenetics of Autoimmune Cholestasis
por: Trivedi, Palak J., et al.
Publicado: (2016)

Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management
por: Milkiewicz, Piotr, et al.
Publicado: (2020)

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved
por: Yoneda, Masato, et al.
Publicado: (2023)

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2018)

Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury
por: Petrescu, Anca D., et al.
Publicado: (2021)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Primary Biliary Cholangitis: Promising Emerging Innovative Therapies and Their Impact on GLOBE Scores
por: Sohal, Aalam, et al.
Publicado: (2023)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)

Neonatal cholestasis due to primary sclerosing cholangitis
por: Shetty, Naman Sadanand, et al.
Publicado: (2016)

Anxiety and Depression in Patients with Primary Biliary Cholangitis: Current Insights and Impact on Quality of Life
por: Sivakumar, Tarika, et al.
Publicado: (2021)

PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
por: Trauner, Michael, et al.
Publicado: (2023)

Determination of Tropifexor in Beagle Dog Plasma by UPLC-MS/MS and Its Application in Pharmacokinetics
por: Su, Yan-Ding, et al.
Publicado: (2022)

Arbutin Alleviates the Liver Injury of α-Naphthylisothiocyanate-induced Cholestasis Through Farnesoid X Receptor Activation
por: Wu, Peijie, et al.
Publicado: (2021)

Mechanism and Active Components of Qingre Lidan Tablets Alleviate Intrahepatic Cholestasis by Activating the Farnesoid X Receptor
por: Xia, Yafei, et al.
Publicado: (2022)

Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise
por: Corrigan, Margaret, et al.
Publicado: (2019)

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2020)

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
por: Sanyal, Arun J., et al.
Publicado: (2023)

Promoter DNA Methylation of Farnesoid X Receptor and Pregnane X Receptor Modulates the Intrahepatic Cholestasis of Pregnancy Phenotype
por: Cabrerizo, Romina, et al.
Publicado: (2014)

PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)
por: Stinton, Laura M., et al.
Publicado: (2014)

Intrahepatic Cholestasis of Pregnancy Levels of Sulfated Progesterone Metabolites Inhibit Farnesoid X Receptor Resulting in a Cholestatic Phenotype
por: Abu-Hayyeh, Shadi, et al.
Publicado: (2013)

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2023)

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
por: Anstee, Quentin M., et al.
Publicado: (2023)

Calculus Bovis Sativus Improves Bile Acid Homeostasis via Farnesoid X Receptor-Mediated Signaling in Rats With Estrogen-Induced Cholestasis
por: Xiang, Dong, et al.
Publicado: (2019)

Progressive familial intrahepatic cholestasis — farnesoid X receptor deficiency due to NR1H4 mutation: A case report
por: Czubkowski, Piotr, et al.
Publicado: (2021)

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
por: Parés, Albert, et al.
Publicado: (2020)

Intrahepatic macrophage populations in the pathophysiology of primary sclerosing cholangitis
por: Chen, Yung-Yi, et al.
Publicado: (2019)

Oncomir MicroRNA-346 Is Upregulated in Colons of Patients With Primary Sclerosing Cholangitis
por: Kempinska-Podhorodecka, Agnieszka, et al.
Publicado: (2020)

Role of miR-506 in ulcerative colitis associated with primary sclerosing cholangitis
por: Kempinska-Podhorodecka, Agnieszka, et al.
Publicado: (2021)

β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor
por: Klag, Thomas, et al.
Publicado: (2018)

Paeoniflorin alleviates 17α-ethinylestradiol-induced cholestasis via the farnesoid X receptor-mediated bile acid homeostasis signaling pathway in rats
por: Wang, Rulin, et al.
Publicado: (2022)

Protection against oxidative stress mediated by the Nrf2/Keap1 axis is impaired in Primary Biliary Cholangitis
por: Wasik, Urszula, et al.
Publicado: (2017)

Suppression of Hepatic PPARα in Primary Biliary Cholangitis Is Modulated by miR-155
por: Adamowicz, Monika, et al.
Publicado: (2022)

Effects of Melittin Treatment in Cholangitis and Biliary Fibrosis in a Model of Xenobiotic-Induced Cholestasis in Mice
por: Kim, Kyung-Hyun, et al.
Publicado: (2015)

Chronic Hepatitis E is associated with cholangitis
por: Beer, Andrea, et al.
Publicado: (2019)

Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis
por: Fischer, Sandra, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_t343h2fdm7sdodo7jr19rju93i